At Polar Nanopharma, Ecopol Tech Spin off, we are seeking for private investment and strategic partners to advance our oncology pipeline targeting highly heterogeneous and aggressive tumor settings with significant unmet medical need, including triple-negative breast cancer, non-small cell lung cancer and Lynch syndrome-associated cancers, the latter being developed in co-development with Hospital Clínic de Barcelona.

____________________________________________________________________________________________

🇪🇸 Polar NanoPharma, spin-off de Ecopol Tech, buscamos Inversión y socios estratégicos para avanzar nuestro pipeline oncológico dirigido a tumores altamente heterogéneos y agresivos con elevada necesidad médica no cubierta, incluyendo cáncer de mama triple negativo, cáncer de pulmón no microcítico y cánceres asociados al síndrome de Lynch, este último en co-desarrollo con el Hospital Clínic de Barcelona.

Seeking partners interested in licensing opportunities, co-development projects and tailor-made R&D programs, including custom formulation development, encapsulation of active ingredients, polymer design, analytical characterization and scale-up support in polymers and nanomedicines.

In parallel, Polar NanoPharma, a spin-off of Ecopol Tech focused on nanoparticle-based cancer therapies, is seeking funding and strategic investment partners to advance its oncology pipeline targeting highly heterogeneous and aggressive tumor settings with significant unmet medical need, including triple-negative breast cancer, non-small cell lung cancer and Lynch syndrome-associated cancers, the latter being developed in co-development with Hospital Clínic de Barcelona.

🇪🇸 ES

Ecopol Tech busca socios interesados en oportunidades de licencia, proyectos de co-desarrollo y programas de I+D a medida, incluyendo desarrollo de formulaciones personalizadas, encapsulación de ingredientes activos, diseño de polímeros, caracterización analítica y soporte al escalado en polímeros y nanomedicinas.

En paralelo, Polar NanoPharma, spin-off de Ecopol Tech centrada en terapias nanoparticuladas frente al cáncer, busca financiación y socios estratégicos de inversión para avanzar en su pipeline oncológico dirigido a tumores altamente heterogéneos y agresivos con elevada necesidad médica no cubierta, incluyendo cáncer de mama triple negativo, cáncer de pulmón no microcítico y cánceres asociados al síndrome de Lynch, este último en co-desarrollo con el Hospital Clínic de Barcelona.

Pre-coloured ABS plastics are widely used materials in external enclosures applications of medical devices.

Especially in parenteral drug de livery medical devices (medical devices designed to deliver a specific medicine to the patient through parenteral paths e.g. via mucosa (e.g. absorption through the lungs) or IV),  biocompatibility is a key property that needs to be complied to fulfil with medical regulations (e.g. EU MDR or US FDA regulatory requirements). Final medical devices must be tested according to ISO 10993 and it is the responsibility of the Medical OEM manufacturer to make sure that such tests are conducted and passed. Biocompatibility tests are expensive and there is the risk that the required medical device may not pass one or more of them. The implementation of specific production procedures like GMPs (Good Manufacturing Practices), clean rooms etc. is critical, but positive test results cannot be assured without the correct pre-selection of all materials needed to produce each component of the device.

In addition, medical device bright and intense colours are relevant for patients because they stimulate a positive attitude to take the drug medication, they help the distinction of different device part and facilitate the way how to use the device itself. They help to distinguish different types of drugs that are targeting to different types of diseases. Despite colour in medical device applications is such a key property, there are strict regulatory limitations in the type of pigments admitted in the colour formulations, and in their maximum allowed concentrations. When the biocompatibility requirement according to ISO 10993 must be met, not only the base ABS material must be biocompatible but also all the additives compounded with the material, including the colour formulation with all its different pigments. No biocompatible pigments must be directly excluded, and maximum allowed pigment concentrations must not be exceeded. Furthermore, special attention must be given to possible mutual interactions among different pigments, ABS material and other additives. ELIX Polymers eliminates those risks to OEMs, processors and developers providing a medical precoloured ABS material formulation that includes the complete colour recipe and does not need any further material modification. The complete formulation has been fully reviewed and pre-tested to meet biocompatibility according to ISO 10993 and other regulatory requirements. This is a much safer approach for medical OEMs and moulders instead of choosing a medical ABS in natural colour and compound it themselves with a masterbatch colour, during the injection   moulding process.

Concienciar a las empresas biotech y farmacéuticas de que, sin una buena ciberseguridad, pueden perder todo el progreso que se está haciendo.

Evimatic® is seeking partners in the mental health or ADHD space. We look for organizations developing, marketing or distributing diagnostic and monitoring tools that wish to enhance their value proposition with our transparent and customizable evidence-analysis AI technology:

1. Digital Health Providers (ADHD Diagnosis, Screening and ADHD symptom severity tracking): We are looking to collaborate with companies that market digital technologies for ADHD diagnosis or screening. Our goal is to create a comprehensive solution by integrating Evimatic’s advanced treatment analysis, providing clinicians and patients with a seamless end-to-end solution—from initial detection to evidence-based therapeutic selection.
2. Technology Distributors: We are seeking experienced distributors of technological solutions with a specialized interest in the ADHD, neurodevelopmental disorders, and child and adolescent mental health markets. We offer a unique, high-value tool that addresses the critical gap in ADHD therapeutics knowledge management, designed to be a cornerstone in the portfolio of distributors serving specialized clinics, hospitals, and educational institutions.

By partnering with Evimatic, organizations can leverage our transparent AI reasoning to provide comprehensive ADHD therapeutics knowledge management, ensuring that professionals have immediate access to the most recent and relevant scientific information.

Network Development

Network Development